Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use
Por:
Deleuran, M, Marcoux, D, De Bruin-Weller, MS, Irvine, AD, Baselga E, Ahn, K, Castro, AP, Bansal, A, Chao, JD, Bego-Le Bagousse, G and Rossi, AB
Publicada:
1 jul 2021
Resumen:
Filiaciones:
Deleuran, M:
Aarhus Univ Hosp, Dept Dermatol, Aarhus, Denmark
Marcoux, D:
Univ Montreal, Div Dermatol, Dept Pediat, Montreal, PQ, Canada
Ctr Hosp Univ St Justine, Montreal, PQ, Canada
De Bruin-Weller, MS:
Univ Med Ctr Utrecht, Dept Dermatol & Allergol, Natl Expertise Ctr Atop Dermatitis, Utrecht, Netherlands
Irvine, AD:
Trinity Coll Dublin, Med Clin, Dublin, Ireland
Our Ladys Childrens Hosp Crumlin, Natl Childrens Res Ctr, Dublin, Ireland
Baselga E:
Hosp Santa Creu & Sant Pau, Dept Dermatol, Barcelona, Spain
Ahn, K:
Sungkyunkwan Univ, Dept Pediat, Samsung Med Ctr, Sch Med, Seoul, South Korea
Castro, AP:
Univ Sao Paulo HC FMUSP, Inst Crianca, Hosp Clin, Allergy & Immunol Div,Pediat Dept,Fac Med, Sao Paulo, SP, Brazil
Bansal, A:
Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
Chao, JD:
Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
Bego-Le Bagousse, G:
Sanofi, Chilly Mazarin, France
Rossi, AB:
Sanofi Genzyme, Cambridge, MA USA
Green Submitted, gold
|